Sofinnova Investments, Inc. Abb Vie Inc. Transaction History

Sofinnova Investments, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $41.2 Million - $51.1 Million	-312,018 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $4.23 Million - $5.36 Million	39,418 Added 14.46%	312,018 $42.2 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $29 Million - $32.9 Million	272,600 New	272,600 $29.4 Million
Q1 2021 May 14, 2021	SELL	$102.3 - $112.62 $30 Million - $33.1 Million	-293,596 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $3.84 Million - $5.19 Million	-47,744 Reduced 13.99%	293,596 $31.5 Million
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $7.68 Million - $9.01 Million	89,381 Added 35.47%	341,340 $29.9 Million
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $14.8 Million - $19.8 Million	201,959 Added 403.92%	251,959 $24.7 Million
Q1 2020 May 13, 2020	BUY	$64.5 - $97.79 $3.23 Million - $4.89 Million	50,000 New	50,000 $3.81 Million
Q3 2019 Nov 14, 2019	SELL	$62.98 - $75.72 $1.82 Million - $2.19 Million	-28,911 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$65.7 - $83.98 $1.9 Million - $2.43 Million	28,911 New	28,911 $2.1 Million

3,855

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.